福建省新报告HIV/AIDS中HIV-1原发耐药状况研究
|
摘要
目的研究福建省HIV-1原发耐药者的流行病学特征,为制定艾滋病抗病毒治疗策略提供依据。方法收集福建省2015—2016年新报告且未接受过抗病毒治疗的HIV/AIDS个案信息903例,采用in-house基因型耐药检测法分析耐药突变位点。用logistic回归模型分析影响HIV原发耐药传播的危险因素。结果 903例研究对象以男性为主(85.7%);20～39岁组居多(56.9%);以性接触传播为主(97.1%);HIV-1感染者中40例被检出耐药突变,原发耐药率为4.4%。针对非核苷类逆转录酶抑制剂(NNRTI)耐药突变位点共11个,常见是V179D/E/F/T、E138G/A和G190A/E/D;针对核苷类类逆转录酶抑制剂(NRTI)耐药突变位点共8个,常见是T215D/A/P/S、A62V和M184V/R/L/W;针对蛋白酶抑制剂(PI)耐药突变位点共12个,常见是L33F、Q58E和M46I。结论福建省新报告HIV-1感染者中HIV-1原发耐药率尚处于低流行水平,但应继续保持对HIV耐药株传播的监测。
Objective To investigate the epidemiological characteristics of cases with HIV-1 primary drug resistance in newly reported HIV/AIDS infection in Fujian for disease control and prevention. Methods Totally 903 newly reported HIV/AIDS cases without antiviral treatment in Fujian from 2015 to 2016 were collected. The genotype drug resistance mutations of HIV were analyzed with in-house nested reverse transcript polymerase chain reaction(RT-PCR) technology. The risk factors affecting the transmission of primary HIV-1 drug resistance were analyzed by logistic regression model. Results In the 903 cases, the male case was 85.7%, the group aged 20-39 was 56.9% and the route by sexually transmission was 97.1%.Totally 40 cases were detected to have HIV drug resistance mutations with the overall primary HIV drug resistance rate of 4.4%.There were eleven mutation sites for non-nucleoside reverse transcriptase inhibitors(NNRTI), including common V179 D/E/F/T, E138 G/A and G190 A/E/D. Eight mutation sites for nucleoside reverse transcriptase inhibitors(NRTI),including common T215 D/A/P/S, A62 V and M184 V/R/L/W. Twelve mutation sites for protease inhibitors(PI), including common L33 F, Q58 E and M46 I. Conclusion The primary drug resistant of HIV-1 strains infection in newly reported HIV/AIDS cases in Fujian was at low epidemic level. It is necessary to keep on monitoring in the future.
Objective To investigate the epidemiological characteristics of cases with HIV-1 primary drug resistance in newly reported HIV/AIDS infection in Fujian for disease control and prevention. Methods Totally 903 newly reported HIV/AIDS cases without antiviral treatment in Fujian from 2015 to 2016 were collected. The genotype drug resistance mutations of HIV were analyzed with in-house nested reverse transcript polymerase chain reaction(RT-PCR) technology. The risk factors affecting the transmission of primary HIV-1 drug resistance were analyzed by logistic regression model. Results In the 903 cases, the male case was 85.7%, the group aged 20-39 was 56.9% and the route by sexually transmission was 97.1%.Totally 40 cases were detected to have HIV drug resistance mutations with the overall primary HIV drug resistance rate of 4.4%.There were eleven mutation sites for non-nucleoside reverse transcriptase inhibitors(NNRTI), including common V179 D/E/F/T, E138 G/A and G190 A/E/D. Eight mutation sites for nucleoside reverse transcriptase inhibitors(NRTI),including common T215 D/A/P/S, A62 V and M184 V/R/L/W. Twelve mutation sites for protease inhibitors(PI), including common L33 F, Q58 E and M46 I. Conclusion The primary drug resistant of HIV-1 strains infection in newly reported HIV/AIDS cases in Fujian was at low epidemic level. It is necessary to keep on monitoring in the future.
引文
[1] PALELLA FJ JR,DELANEY KM,MOORMAN AC,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators[J].N Engl J Med.1998,338:853-860.
[2] HOGG RS,YIP B,KULLY C,et al.Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens[J].CMAJ.1999,160:659-665.
[3] GUNTHARD HF, ABERG JA, ERON JJ,et al.Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel[J].JAMA.2014, 312:410-425.
[4] 邵一鸣,李敬云,康来仪,等.HIV耐药检测策略和检测技术[M].北京:人民卫生出版社.2010:2-4, 114-134.
[5] WHO.Guidelines for surveillance of HIV drug resistance[R].2003:30-36.
[6] WHO.Tackling HIV drug resistance: trends, guidelines and global action[R].2017.
[7] 王征桦,张春阳,吴守丽等.福建省抗病毒治疗艾滋病患者耐药的影响因素分析[J].海峡预防医学杂志,2018,24(5):10-11.
[8] 刘大锦,冯孟贤,刘民.中国未接受抗病毒治疗的人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)人群HIV原发耐药的Meta分析[J].北京大学学报:医学版,2015,3:474-482.
[9] 中国疾病预防控制中心.国家免费艾滋病抗病毒治疗手册:4版.人民卫生出版社,2016:57-58.
[2] HOGG RS,YIP B,KULLY C,et al.Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens[J].CMAJ.1999,160:659-665.
[3] GUNTHARD HF, ABERG JA, ERON JJ,et al.Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel[J].JAMA.2014, 312:410-425.
[4] 邵一鸣,李敬云,康来仪,等.HIV耐药检测策略和检测技术[M].北京:人民卫生出版社.2010:2-4, 114-134.
[5] WHO.Guidelines for surveillance of HIV drug resistance[R].2003:30-36.
[6] WHO.Tackling HIV drug resistance: trends, guidelines and global action[R].2017.
[7] 王征桦,张春阳,吴守丽等.福建省抗病毒治疗艾滋病患者耐药的影响因素分析[J].海峡预防医学杂志,2018,24(5):10-11.
[8] 刘大锦,冯孟贤,刘民.中国未接受抗病毒治疗的人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)人群HIV原发耐药的Meta分析[J].北京大学学报:医学版,2015,3:474-482.
[9] 中国疾病预防控制中心.国家免费艾滋病抗病毒治疗手册:4版.人民卫生出版社,2016:57-58.